

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Claims 1-38 (Canceled).

Claim 39 (New): An antiviral pharmaceutical composition having anti-HBV activity for treating HBV infection comprising a therapeutically effective amount of SEQ ID NO: 24 and a pharmaceutically acceptable carrier, the anti-HBV activity of said SEQ ID NO: 24 occurs by a non-sequence complementary mode of action.

Claim 40 (New): An antiviral pharmaceutical composition having anti-HBV activity for treating HBV infection comprising a therapeutically effective amount of REP 2006 and a pharmaceutically acceptable carrier, the anti-HBV activity of said REP 2006 occurs by a non-sequence complementary mode of action.

Claim 41 (New): An antiviral pharmaceutical composition having anti-HBV activity for treating HBV infection comprising a therapeutically effective amount of SEQ ID NO: 22 and a pharmaceutically acceptable carrier, the anti-HBV activity of said SEQ ID NO: 22 occurs by a non-sequence complementary mode of action.